Estradiol/dydrogesterone

Drug Profile

Estradiol/dydrogesterone

Alternative Names: Femoston; Femoston Conti; Femoston Conti Low-dose; Femoston Continous

Latest Information Update: 24 Feb 2010

Price : $50

At a glance

  • Originator Solvay Pharmaceuticals
  • Developer Abbott Laboratories
  • Class Estradiol congeners; Estrenes; Hormonal replacements; Pregnadienes
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Menopausal syndrome; Postmenopausal osteoporosis

Most Recent Events

  • 16 Feb 2010 Solvay Pharmaceuticals has been acquired and merged into Abbott Laboratories
  • 26 Nov 2001 Launched for Postmenopausal osteoporosis prevention in Europe (PO)
  • 14 Nov 2001 A study has been added to the adverse events and Women's Health therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top